Cue Biopharma, Inc.
CUE
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$0.26
FAIR PRICE
$0.18
MARGIN
$0.08
P/E Ratio
N/A
Div. Yield
N/A
ROE
-165.2%
Market Cap
$21M
Small-cap
COMING SOON
Get notified when CUE's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Usman Azam
COUNTRY
US
HEADQUARTERS
Boston
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate CUE's fair price
Cue Biopharma, Inc.'s fair price of $0.18 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $0.26, CUE trades 30.8% above its calculated fair value.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting CUE's risk profile.
RELATIVE · 30%
Comparing CUE's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for CUE, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for CUE.
Explore on BuliosFAQ
What is the fair price of CUE?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Cue Biopharma, Inc. is $0.18. At the current market price of $0.26, CUE trades 30.8% above its calculated fair value.
Is CUE overvalued or undervalued?+
Cue Biopharma, Inc. is currently overvalued based on our valuation model. The stock trades at $0.26, which is 30.8% above the fair price of $0.18.
How often is CUE's fair price updated?+
We update fair price calculations for CUE daily after market close. The current fair price of $0.18 incorporates the latest market data and sector multiples.
What factors affect CUE's fair price calculation?+
CUE's fair price of $0.18 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -165.2%.
Is CUE a good buy right now?+
At $0.26, CUE trades 30.8% above our fair value estimate of $0.18. The stock is currently overvalued. ROE stands at -165.2% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does CUE pay dividends?+
CUE does not currently pay a dividend.